Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. The company is headquartered in Broomfield, Colorado and currently employs 11 full-time employees. The company went IPO on 2022-04-22. The firm leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The firm has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.
Mr. Brent Ness is the President of Aclarion Inc, joining the firm since 2021.
What is the price performance of ACON stock?
The current price of ACON is $3.19, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Aclarion Inc?
Aclarion Inc belongs to Health Care industry and the sector is Health Care
What is Aclarion Inc market cap?
Aclarion Inc's current market cap is $7.2M
Is Aclarion Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Aclarion Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell